Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH/gL pentamer potently block primary cytotrophoblast infection

Journal of Virology

Volumn 89, Issue 23, 2015, Pages 11884-11898

  Chiuppesi, Flavia ^a   Wussow, Felix ^a   Johnson, Erica ^b   Bian, Chao ^a   Zhuo, Meng ^a   Rajakumar, Augustine ^b   Barry, Peter A ^c   Britt, William J ^d   Chakraborty, Rana ^b   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; MODIFIED VACCINIA VIRUS ANKARA PENTAMER COMPLEX VACCINE; NEUTRALIZING ANTIBODY; POXVIRUS VECTOR; UNCLASSIFIED DRUG; GLYCOPROTEIN H, CYTOMEGALOVIRUS; MEMBRANE PROTEIN; MULTIPROTEIN COMPLEX; UL128 PROTEIN, HUMAN CYTOMEGALOVIRUS; UL130 PROTEIN, HUMAN CYTOMEGALOVIRUS; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; DRUG RESPONSE; INFECTION PREVENTION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; VACCINIA VIRUS; VERTICAL TRANSMISSION; VIRUS ENTRY; VIRUS IDENTIFICATION; ANIMAL; CELL LINE; CYTOMEGALOVIRUS INFECTIONS; IMMUNOBLOTTING; IMMUNOLOGY; PREVENTION AND CONTROL; SERODIAGNOSIS; TROPHOBLAST; VIROLOGY;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; IMMUNOBLOTTING; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MICE; MULTIPROTEIN COMPLEXES; NEUTRALIZATION TESTS; TROPHOBLASTS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS INTERNALIZATION;

EID: 84949648626     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01701-15     Document Type: Article

References (86)

1. Ludwig A, Hengel H. 2009. Epidemiological impact and disease burden of congenital cytomegalovirus infection in Europe. Euro Surveill 14:26-32.
2. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. 2013. The "silent" global burden of congenital cytomegalovirus. Clin Microbiol Rev 26:86-102. http://dx.doi.org/10.1128/CMR.00062-12.
3. Ornoy A, Diav-Citrin O. 2006. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy. Reprod Toxicol 21:399-409. http://dx.doi.org/10.1016/j.reprotox.2005.02.002.
4. Cannon MJ, Davis KF. 2005. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health 5:70. http://dx.doi.org/10.1186/1471-2458-5-70.
5. Britt W. 2015. Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy. Med Microbiol Immunol 204:263-271. http://dx.doi.org/10.1007/s00430-015-0399-9.
6. Kenneson A, Cannon MJ. 2007. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 17:253-276. http://dx.doi.org/10.1002/rmv.535.
7. Cannon MJ, Westbrook K, Levis D, Schleiss MR, Thackeray R, Pass RF. 2012. Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus. Prev Med 54:351-357. http://dx.doi.org/10.1016/j.ypmed.2012.03.009.
8. Pass RF, Anderson B. 2014. Mother-to-child transmission of cytomegalovirus and prevention of congenital infection. J Pediatr Infect Dis Soc 3:S2-S6. http://dx.doi.org/10.1093/jpids/piu069.
9. Lazzarotto T, Gabrielli L, Guerra B, Cervi F, Piccirilli G, Simonazzi G, Chiereghin A, Bellini F, Landini MP. 2014. Diagnosis and prognosis of congenitalCMVinfection: a case report and review of the literature. Scand J Clin Lab Invest Suppl 244:34-40. http://dx.doi.org/10.3109/00365513.2014.936679.
10. Pereira L, Petitt M, Fong A, Tsuge M, Tabata T, Fang-Hoover J, Maidji E, Zydek M, Zhou Y, Inoue N, Loghavi S, Pepkowitz S, Kauvar LM, Ogunyemi D. 2014. Intrauterine growth restriction caused by underlying congenital cytomegalovirus infection. J Infect Dis 209:1573-1584. http://dx.doi.org/10.1093/infdis/jiu019.
11. La Rosa C, Diamond DJ. 2012. The immune response to human CMV. Future Virol 7:279-293. http://dx.doi.org/10.2217/fvl.12.8.
12. Khanna R, Diamond DJ. 2006. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med 12:26-33. http://dx.doi.org/10.1016/j.molmed.2005.11.006.
13. Dasari V, Smith C, Khanna R. 2013. Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Rev Vaccines 12:661-676. http://dx.doi.org/10.1586/erv.13.46.
14. Stratton KR, Durch JS, Lawrence RS. 2000. Vaccines for the 21st century: a tool for decision-making. National Academy Press, Washington, DC.
15. Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA. 2013. Priorities for CMV vaccine development. Vaccine 32:4-10. http://dx.doi.org/10.1016/j.vaccine.2013.09.042.
16. Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P, Bialek S. 2013. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 31(Suppl 2):B197-B203. http://dx.doi.org/10.1016/j.vaccine.2012.10.074.
17. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, Corey L, Hill J, Davis E, Flanigan C, Cloud G. 2009. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 360:1191-1199. http://dx.doi.org/10.1056/NEJMoa0804749.
18. Pass RF. 2009. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 46(Suppl 4):S73-S76. http://dx.doi.org/10.1016/j.jcv.2009.07.002.
19. Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O'Beirne J, Thorburn D, Patch D, Atkinson CE, Pichon S, Sweny P, Lanzman M, Woodford E, Rothwell E, Old N, Kinyanjui R, Haque T, Atabani S, Luck S, Prideaux S, Milne RS, Emery VC, Burroughs AK. 2011. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet 377:1256-1263. http://dx.doi.org/10.1016/S0140-6736(11)60136-0.
20. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Edwards KM, Stanberry LR, Pichon S, Amegashie C, Bellamy AR. 2014. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls, poster 1113. Abstr IDWeek, Philadelphia, Pennsylvania, 8 to 12 October 2014.
21. Wang D, Shenk T. 2005. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci U S A 102:18153-18158. http://dx.doi.org/10.1073/pnas.0509201102.
22. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC. 2006. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80:710-722. http://dx.doi.org/10.1128/JVI.80.2.710-722.2006.
23. Vanarsdall AL, Johnson DC. 2012. Human cytomegalovirus entry into cells. Curr Opin Virol 2:37-42. http://dx.doi.org/10.1016/j.coviro.2012.01.001.
24. Ryckman BJ, Chase MC, Johnson DC. 2008. HCMV gH/gL/UL128-131 interferes with virus entry into epithelial cells: evidence for cell typespecific receptors. Proc Natl Acad Sci U S A 105:14118-14123. http://dx.doi.org/10.1073/pnas.0804365105.
25. Hahn G, Revello MG, Patrone M, Percivalle E, Campanini G, Sarasini A, Wagner M, Gallina A, Milanesi G, Koszinowski U, Baldanti F, Gerna G. 2004. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 78:10023-10033. http://dx.doi.org/10.1128/JVI.78.18.10023-10033.2004.
26. Wang D, Yu QC, Schroer J, Murphy E, Shenk T. 2007. Human cytomegalovirus uses two distinct pathways to enter retinal pigmented epithelial cells. Proc Natl Acad Sci U S A 104:20037-20042. http://dx.doi.org/10.1073/pnas.0709704104.
27. Wille PT, Knoche AJ, Nelson JA, Jarvis MA, Johnson DC. 2010. A human cytomegalovirus gO-null mutant fails to incorporate gH/gL into the virion envelope and is unable to enter fibroblasts and epithelial and endothelial cells. J Virol 84:2585-2596. http://dx.doi.org/10.1128/JVI.02249-09.
28. Vanarsdall AL, Chase MC, Johnson DC. 2011. Human cytomegalovirus glycoprotein gO complexes with gH/gL, promoting interference with viral entry into human fibroblasts but not entry into epithelial cells. J Virol 85:11638-11645. http://dx.doi.org/10.1128/JVI.05659-11.
29. Ciferri C, Chandramouli S, Donnarumma D, Nikitin PA, Cianfrocco MA, Gerrein R, Feire AL, Barnett SW, Lilja AE, Rappuoli R, Norais N, Settembre EC, CarfiA. 2015. Structural and biochemical studies of HCMVgH/gL/gO and Pentamer reveal mutually exclusive cell entry complexes. Proc Natl Acad Sci U S A 112:1767-1772. http://dx.doi.org/10.1073/pnas.1424818112.
30. Li G, Nguyen CC, Ryckman BJ, Britt WJ, Kamil JP. 2015. A viral regulator of glycoprotein complexes contributes to human cytomegalovirus cell tropism. Proc Natl Acad Sci U S A 112:4471-4476. http://dx.doi.org/10.1073/pnas.1419875112.
31. Zhou M, Lanchy JM, Ryckman BJ. 2015. Human cytomegalovirus gH/gL/gO promotes the fusion step of entry into all cell types, whereas gH/gL/UL128-131 broadens virus tropism through a distinct mechanism. J Virol 89:8999-9009. http://dx.doi.org/10.1128/JVI.01325-15.
32. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, Revello MG, Gerna G, Sallusto F, Lanzavecchia A. 2010. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84:1005-1013. http://dx.doi.org/10.1128/JVI.01809-09.
33. Kabanova A, Perez L, Lilleri D, Marcandalli J, Agatic G, Becattini S, Preite S, Fuschillo D, Percivalle E, Sallusto F, Gerna G, Corti D, Lanzavecchia A. 2014. Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proc Natl Acad SciUSA111:17965-17970. http://dx.doi.org/10.1073/pnas.1415310111.
34. Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM. 2013. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 110:E4997-E5005. http://dx.doi.org/10.1073/pnas.1316517110.
35. Wen Y, Monroe J, Linton C, Archer J, Beard CW, Barnett SW, Palladino G, Mason PW, CarfiA, Lilja AE. 2014. Human cytomegalovirus gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine 32:3796-3804. http://dx.doi.org/10.1016/j.vaccine.2014.05.004.
36. Wussow F, Chiuppesi F, Martinez J, Campo J, Johnson E, Flechsig C, Newell M, Tran E, Ortiz J, La Rosa C, Herrmann A, Longmate J, Chakraborty R, Barry PA, Diamond DJ. 2014. Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524. http://dx.doi.org/10.1371/journal.ppat.1004524.
37. Cui X, Meza BP, Adler SP, McVoy MA. 2008. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 26:5760-5766. http://dx.doi.org/10.1016/j.vaccine.2008.07.092.
38. Gerna G, Sarasini A, Patrone M, Percivalle E, Fiorina L, Campanini G, Gallina A, Baldanti F, Revello MG. 2008. Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection. J Gen Virol 89:853-865.http://dx.doi.org/10.1099/vir.0.83523-0.
39. Revello MG, Gerna G. 2010. Human cytomegalovirus tropism for endothelial/epithelial cells: scientific background and clinical implications. Rev Med Virol 20:136-155. http://dx.doi.org/10.1002/rmv.645.
40. Pereira L, Maidji E, McDonagh S, Tabata T. 2005. Insights into viral transmission at the uterine-placental interface. Trends Microbiol 13:164-174.http://dx.doi.org/10.1016/j.tim.2005.02.009.
41. Pereira L, Maidji E. 2008. Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 325:383-395.
42. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L. 2006. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168: 1210-1226. http://dx.doi.org/10.2353/ajpath.2006.050482.
43. McDonagh S, Maidji E, Chang HT, Pereira L. 2006. Patterns of human cytomegalovirus infection in term placentas: a preliminary analysis. J Clin Virol 35:210-215. http://dx.doi.org/10.1016/j.jcv.2005.08.011.
44. Tabata T, McDonagh S, Kawakatsu H, Pereira L. 2007. Cytotrophoblasts infected with a pathogenic human cytomegalovirus strain dysregulate cell-matrix and cell-cell adhesion molecules: a quantitative analysis. Placenta 28:527-537. http://dx.doi.org/10.1016/j.placenta.2006.05.006.
45. Trincado DE, Munro SC, Camaris C, Rawlinson WD. 2005. Highly sensitive detection and localization of maternally acquired human cytomegalovirus in placental tissue by in situ polymerase chain reaction. J Infect Dis 192:650-657. http://dx.doi.org/10.1086/431999.
46. Fisher S, Genbacev O, Maidji E, Pereira L. 2000. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol 74:6808-6820. http://dx.doi.org/10.1128/JVI.74.15.6808-6820.2000.
47. Yamamoto-Tabata T, McDonagh S, Chang HT, Fisher S, Pereira L. 2004. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cy-totrophoblast invasiveness in vitro. J Virol 78:2831-2840. http://dx.doi.org/10.1128/JVI.78.6.2831-2840.2004.
48. Rauwel B, Mariame B, Martin H, Nielsen R, Allart S, Pipy B, Mandrup S, Devignes MD, Evain-Brion D, Fournier T, Davrinche C. 2010. Activation of peroxisome proliferator-activated receptor gamma by human cytomegalovirus for de novo replication impairs migration and invasiveness of cytotrophoblasts from early placentas. J Virol 84:2946-2954. http://dx.doi.org/10.1128/JVI.01779-09.
49. Zydek M, Petitt M, Fang-Hoover J, Adler B, Kauvar LM, Pereira L, Tabata T. 2014. HCMV infection of human trophoblast progenitor cells of the placenta is neutralized by a human monoclonal antibody to glycoprotein B and not by antibodies to the pentamer complex. Viruses 6:1346-1364.http://dx.doi.org/10.3390/v6031346.
50. Kauvar LM, Liu K, Park M, DeChene N, Stephenson R, Tenorio E, Ellsworth SL, Tabata T, Petitt M, Tsuge M, Fang-Hoover J, Adler SP, Cui X, McVoy MA, Pereira L. 2015. A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types. Antimicrob Agents Chemother 59:1558-1568. http://dx.doi.org/10.1128/AAC.04295-14.
51. Meyer H, Sutter G, Mayr A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virusMVAand their influence on virulence. J Gen Virol 72(Pt 5):1031-1038. http://dx.doi.org/10.1099/0022-1317-72-5-1031.
52. Harrer E, Bauerle M, Ferstl B, Chaplin P, Petzold B, Mateo L, Handley A, Tzatzaris M, Vollmar J, Bergmann S, Rittmaier M, Eismann K, Muller S, Kalden JR, Spriewald B, Willbold D, Harrer T. 2005. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10:285-300.
53. Johnson EL, Chakraborty R. 2012. Placental Hofbauer cells limit HIV-1 replication and potentially offset mother-to-child transmission (MTCT) by induction of immunoregulatory cytokines. Retrovirology 9:101. http://dx.doi.org/10.1186/1742-4690-9-101.
54. Tang Z, Tadesse S, Norwitz E, Mor G, Abrahams VM, Guller S. 2011. Isolation of Hofbauer cells from human term placentas with high yield and purity. AmJ Reprod Immunol 66:336-348. http://dx.doi.org/10.1111/j.1600-0897.2011.01006.x.
55. Johnson EL, Chu H, Byrareddy SN, Spearman P, Chakraborty R. 2015. Placental Hofbauer cells assemble and sequester HIV-1 in tetraspaninpositive compartments that are accessible to broadly neutralizing antibodies. J Int AIDS Soc 18:19385. http://dx.doi.org/10.7448/IAS.18.1.19385.
56. Maldonado-Estrada J, Menu E, Roques P, Barre-Sinoussi F, Chaouat G. 2004. Evaluation of cytokeratin 7 as an accurate intracellular marker with which to assess the purity of human placental villous trophoblast cells by flow cytometry. J Immunol Methods 286:21-34. http://dx.doi.org/10.1016/j.jim.2003.03.001.
57. Manoussaka MS, Jackson DJ, Lock RJ, Sooranna SR, Kumpel BM. 2005. Flow cytometric characterisation of cells of differing densities isolated from human term placentae and enrichment of villous trophoblast cells. Placenta 26:308-318. http://dx.doi.org/10.1016/j.placenta.2004.06.008.
58. Potgens AJ, Gaus G, Frank HG, Kaufmann P. 2001. Characterization of trophoblast cell isolations by a modified flow cytometry assay. Placenta 22:251-255. http://dx.doi.org/10.1053/plac.2000.0597.
59. Urban M, Britt W, Mach M. 1992. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific. J Virol 66:1303-1311.
60. Britt WJ, Auger D. 1985. Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res 4:31-36. http://dx.doi.org/10.1016/0168-1702(85)90018-8.
61. Andreoni M, Faircloth M, Vugler L, Britt WJ. 1989. A rapid microneutralization assay for the measurement of neutralizing antibody reactive with human cytomegalovirus. J Virol Methods 23:157-167. http://dx.doi.org/10.1016/0166-0934(89)90129-8.
62. Wussow F, Yue Y, Martinez J, Deere JD, Longmate J, Herrmann A, Barry PA, Diamond DJ. 2013. A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques. J Virol 87:1322-1332. http://dx.doi.org/10.1128/JVI.01669-12.
63. Wang Z, Martinez J, Zhou W, La Rosa C, Srivastava T, Dasgupta A, Rawal R, Li Z, Britt WJ, Diamond D. 2010. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine 28:1547-1557. http://dx.doi.org/10.1016/j.vaccine.2009.11.056.
64. Wang Z, La Rosa C, Maas R, Ly H, Brewer J, Mekhoubad S, Daftarian P, Longmate J, Britt WJ, Diamond DJ. 2004. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J Virol 78:3965-3976. http://dx.doi.org/10.1128/JVI.78.8.3965-3976.2004.
65. Sinzger C, Hahn G, Digel M, Katona R, Sampaio KL, Messerle M, Hengel H, Koszinowski U, Brune W, Adler B. 2008. Cloning and sequencing of a highly productive, endotheliotropic virus strain derived from human cytomegalovirus TB40/E. J Gen Virol 89:359-368. http://dx.doi.org/10.1099/vir.0.83286-0.
66. Zhang C. 2012. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol Biol 901:117-135. http://dx.doi.org/10.1007/978-1-61779-931-0_7.
67. Even-Desrumeaux K, Chames P. 2012. Affinity determination of biotinylated antibodies by flow cytometry. Methods Mol Biol 907:443-449. http://dx.doi.org/10.1007/978-1-61779-974-7_25.
68. Fields C, O'Connell D, Xiao S, Lee GU, Billiald P, Muzard J. 2013. Creation of recombinant antigen-binding molecules derived from hybridomas secreting specific antibodies. Nat Protoc 8:1125-1148. http://dx.doi.org/10.1038/nprot.2013.057.
69. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. 2001. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. NEngl J Med 344:1366-1371. http://dx.doi.org/10.1056/NEJM200105033441804.
70. Fouts AE, Chan P, Stephan JP, Vandlen R, Feierbach B. 2012. Antibodies against the gH/gL/UL128/UL130/UL131 complex comprise the majority of the anti-cytomegalovirus (anti-CMV) neutralizing antibody response in CMV hyperimmune globulin. J Virol 86:7444-7447. http://dx.doi.org/10.1128/JVI.00467-12.
71. Scrivano L, Sinzger C, Nitschko H, Koszinowski UH, Adler B. 2011. HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog 7:e1001256. http://dx.doi.org/10.1371/journal.ppat.1001256.
72. Cui X, Lee R, Adler SP, McVoy MA. 2013. Antibody inhibition of human cytomegalovirus spread in epithelial cell cultures. J Virol Methods 192: 44-50. http://dx.doi.org/10.1016/j.jviromet.2013.04.015.
73. Boppana SB, Britt WJ. 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115-1121. http://dx.doi.org/10.1093/infdis/171.5.1115.
74. Li Z, Woo CJ, Iglesias-Ussel MD, Ronai D, ScharffMD. 2004. The generation of antibody diversity through somatic hypermutation and class switch recombination. Genes Dev 18:1-11. http://dx.doi.org/10.1101/gad.1161904.
75. Frank HG, Genbacev O, Blaschitz A, Chen CP, Clarson L, Evain-Brion D, Gardner L, Malek A, Morrish D, Loke YW, Tarrade A. 2000. Cell culture models of human trophoblast-primary culture of trophoblast: a workshop report. Placenta 21(Suppl A):S120-122. http://dx.doi.org/10.1053/plac.1999.0528.
76. Jacob CL, Lamorte L, Sepulveda E, Lorenz IC, Gauthier A, Franti M. 2013. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology 444:140-147. http://dx.doi.org/10.1016/j.virol.2013.06.002.
77. Buscher N, Paulus C, Nevels M, Tenzer S, Plachter B. 2015. The proteome of human cytomegalovirus virions and dense bodies is conserved across different strains. Med Microbiol Immunol 204:285-293. http://dx.doi.org/10.1007/s00430-015-0397-y.
78. Tabata T, Petitt M, Fang-Hoover J, Rivera J, Nozawa N, Shiboski S, Inoue N, Pereira L. 2012. Cytomegalovirus impairs cytotrophoblastinduced lymphangiogenesis and vascular remodeling in an in vivo human placentation model. Am J Pathol 181:1540-1559. http://dx.doi.org/10.1016/j.ajpath.2012.08.003.
79. Bodeus M, Kabamba-Mukadi B, Zech F, Hubinont C, Bernard P, Goubau P. 2010. Human cytomegalovirus in utero transmission: follow-up of 524 maternal seroconversions. J Clin Virol 47:201-202. http://dx.doi.org/10.1016/j.jcv.2009.11.009.
80. Enders G, Daiminger A, Bader U, Exler S, Enders M. 2011. Intrauterine transmission and clinical outcome of 248 pregnancies with primary cytomegalovirus infection in relation to gestational age. J Clin Virol 52:244-246.http://dx.doi.org/10.1016/j.jcv.2011.07.005.
81. Pereira LT, Petitt M, Zydek M, Fang-Hoover J, Kauvar LM. 2014. Diagnosis of underlying congenitalHCMVinfection in cases of idiopathic intrauterine growth restriction and rescue of placental development by monoclonal antibodies and hyperimmune globulin, abstr 164.CMVPub-lic Health and Policy Conf, Salt Lake City, Utah, 26 and 27 September 2014.
82. Nigro G, Adler SP, La Torre R, Best AM. 2005. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350-1362. http://dx.doi.org/10.1056/NEJMoa043337.
83. Revello MG, Lazzarotto T, Guerra B, Spinillo A, Ferrazzi E, Kustermann A, Guaschino S, Vergani P, Todros T, Frusca T, Arossa A, Furione M, Rognoni V, Rizzo N, Gabrielli L, Klersy C, Gerna G. 2014. A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus. N Engl J Med 370:1316-1326. http://dx.doi.org/10.1056/NEJMoa1310214.
84. de Vries JJ, van Zwet EW, Dekker FW, Kroes AC, Verkerk PH, Vossen AC. 2013. The apparent paradox of maternal seropositivity as a risk factor for congenital cytomegalovirus infection: a population-based prediction model. Rev Med Virol 23:241-249. http://dx.doi.org/10.1002/rmv.1744.
85. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, Genini E, Sallusto F, Lanzavecchia A, Corti D, Gerna G. 2013. Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8:e59863. http://dx.doi.org/10.1371/journal.pone.0059863.
86. Furione M, Rognoni V, Sarasini A, Zavattoni M, Lilleri D, Gerna G, Revello MG. 2013. Slow increase in IgG avidity correlates with prevention of human cytomegalovirus transmission to the fetus. J Med Virol 85: 1960-1967. http://dx.doi.org/10.1002/jmv.23691.